As the final piece of a Series C round that it raised last month, consumer focused connected health business Livongo said it received strategic investment from Humana, bringing the amount raised in the Series C to $49.5 million.
Humana made Livongo’s integrated diabetes management available to some of its members in the first phase of the partnership. It combines a connected glucometer consumer-focused technology with personalized coaching.
Humana agreed to a merger with Aetna last year, a move that could make Livongo’s technology available to a still larger group of users. In addition to Humana, Blue Cross Blue Shield of Massachusetts also became an investor in the Series C round.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Livongo’s connected glucometer uploads readings online and it provides data analytics. It can inform the user’s care team and their social network when blood-glucose levels fall outside of the norm. It can also give coaching insights based on users’ data. The company’s approach is designed to make it easier to integrate technology into the lives of people with chronic conditions.
In a phone interview last month with Livongo CEO Glen Tullman, who also once led Allscripts, he ticked off three criteria that healthcare solutions had to meet to be successful. “It has to be a product that people will love or else they will stop using it. It has to have measurable results and it has to save money. If you can’t deliver savings, there’s no point.”
